each R^{3a} is independently halogen; and

subscript n is an integer from 0 to 3,

or salts and isomers thereof,

wherein the medicament reduces the tumor load of the pancreatic tumor, and wherein the medicament is to be administered with a chemotherapeutic agent.


[0007d] In another aspect of the present disclosure, there is provided a use of the nonsteroidal selective glucocorticoid receptor modulators disclosed herein, in the manufacture of a medicament for treating pancreatic cancer, and wherein the medicament is to be administered with a chemotherapeutic agent.

[0008] In some cases, the chemotherapeutic agent is selected from the group consisting of antimicrotubule agents, alkylating agents, topoisomerase inhibitors, endoplasmic reticulum stress inducing agents, antimetabolites, mitotic inhibitors and combinations thereof. In some cases, the chemotherapeutic agent is a taxane. In some cases, the chemotherapeutic agent is selected from the group consisting of nab-paclitaxel, 5-fluorouracil (5-FU), gemcitabine, cisplatin and capecitabine.

[0009] In some cases, the GRM (e.g., a SGRM, such as a nonsteroidal SGRM) is orally administered. In some cases, the GRM is administered by transdermal application, by a nebulized suspension, or by an aerosol spray.

[0010] In some cases, the effective amount of the GRM (e.g., a SGRM, such as a nonsteroidal SGRM) is a daily dose of between 1 and 100 mg/kg/day, wherein the GRM is administered with at least one chemotherapeutic agent. In some embodiments, the daily dose of the GRM is 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30, 40, 50 60, 70, 80, 90 or 100 mg/kg/day. In some cases, the GRM is administrated for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or 80 weeks.

[0011] In some cases, the GRM (e.g., a SGRM) is a nonsteroidal compound comprising a fused azadecalin structure. In some cases, the fused azadecalin compound is a compound having the following formula:




,

wherein L^1 and L^2 are members independently selected from a bond and unsubstituted alkylene;

R^1 is a member selected from unsubstituted alkyl, unsubstituted heteroalkyl,

What is claimed is:

1. Use of a nonsteroidal selective glucocorticoid receptor modulator in the manufacture of a medicament for treating a subject hosting a non-ACTH-secreting pancreatic tumor, wherein the nonsteroidal selective glucocorticoid receptor modulator is a compound comprising a fused azadecalin structure having the formula:



wherein

L^1 and L^2 are members independently selected from a bond and unsubstituted alkylene;

R^1 is a member selected from unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted heterocycloalkyl, —OR^{1A}, $NR^{1C}R^{1D}$, —$C(O)NR^{1C}R^{1D}$, and —$C(O)OR^{1A}$, wherein

R^{1A} is a member selected from hydrogen, unsubstituted alkyl and unsubstituted heteroalkyl,

R^{1C} and R^{1D} are members independently selected from unsubstituted alkyl and unsubstituted heteroalkyl,

wherein R^{1C} and R^{1D} are optionally joined to form an unsubstituted ring with the nitrogen to which they are attached, wherein said ring optionally comprises an additional ring nitrogen;

R^2 has the formula:



wherein

R^{2G} is a member selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, —CN, and —CF_3;

J is phenyl;

t is an integer from 0 to 5;

X is —$S(O_2)$—; and

R^5 is phenyl optionally substituted with 1-5 R^{5A} groups, wherein
R^{5A} is a member selected from hydrogen, halogen, —OR^{5A1}, $S(O_2)NR^{5A2}R^{5A3}$, —CN, and unsubstituted alkyl, wherein
R^{5A1} is a member selected from hydrogen and unsubstituted alkyl, and
R^{5A2} and R^{5A3} are members independently selected from hydrogen and unsubstituted alkyl, or salts and isomers thereof,
wherein the medicament reduces the tumor load of the pancreatic tumor, and wherein the medicament is to be administered with a chemotherapeutic agent.


2. The use of claim 1, wherein the non-ACTH-secreting pancreatic tumor is an exocrine pancreatic tumor.

3. The use of claim 1, wherein the chemotherapeutic agent is selected from the group consisting of taxanes, alkylating agents, topoisomerase inhibitors, endoplasmic reticulum stress inducing agents, antimetabolites, mitotic inhibitors and combinations thereof.


4. The use of claim 3, wherein the chemotherapeutic agent is a taxane.

5. The use of claim 3, wherein the chemotherapeutic agent is selected from the group consisting of nab-paclitaxel, 5-fluorouracil (5-FU), gemcitabine, cisplatin and capecitabine.

6. The use of claim 1, wherein the nonsteroidal selective glucocorticoid receptor modulator compound is the compound comprising a fused azadecalin structure having the formula:



7. Use of a nonsteroidal selective glucocorticoid receptor modulatorin the manufacture of a medicament for treating a subject hosting a non-ACTH-secreting pancreatic tumor, wherein the nonsteroidal selective glucocorticoid receptor modulator is a compound comprising a heteroaryl ketone fused azadecalin structure having the formula:



wherein

R^1 is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from R^{1a};

each R^{1a} is independently selected from the group consisting of hydrogen, C_{1-6} alkyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, CN, N-oxide, C_{3-8} cycloalkyl, and C_{3-8} heterocycloalkyl;

ring J is selected from the group consisting of a cycloalkyl ring, a heterocycloalkyl ring, an aryl ring and a heteroaryl ring, wherein the heterocycloalkyl and heteroaryl rings have from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S;

each R^2 is independently selected from the group consisting of hydrogen, C_{1-6} alkyl, halogen, $C_{1\ 6}$ haloalkyl, $C_{1\ 6}$ alkoxy, C_{1-6} haloalkoxy, C_{1-6} alkyl-C_{1-6}alkoxy, CN, OH, $NR^{2a}R^{2b}$, $C(O)R^{2a}$, $C(O)OR^{2a}$, $C(O)NR^{2a}R^{2b}$, SR^{2a}, $S(O)R^{2a}$, $S(O)_2R^{2a}$, C_{3-8} cycloalkyl, and C_{3-8} heterocycloalkyl, wherein the heterocycloalkyl groups are optionally substituted with 1-4 R^{2c} groups;

alternatively, two R^2 groups linked to the same carbon are combined to form an oxo group (=O);

alternatively, two R^2 groups are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 R^{2d} groups;

R^{2a} and R^{2b} are each independently selected from the group consisting of hydrogen and C_{1-6} alkyl;

each R^{2c} is independently selected from the group consisting of hydrogen, halogen, hydroxy, C_{1-6} alkoxy, C_{1-6} haloalkoxy, CN, and $NR^{2a}R^{2b}$;

each R^{2d} is independently selected from the group consisting of hydrogen and C_{1-6} alkyl, or two R^{2d} groups attached to the same ring atom are combined to form (=O);

R^3 is selected from the group consisting of phenyl and pyridyl, each optionally substituted with 1-4 R^{3a} groups;


each R^{3a} is independently selected from the group consisting of hydrogen, halogen, and C_{1-6} haloalkyl; and

subscript n is an integer from 0 to 3;


or salts and isomers thereof,

wherein the medicament reduces the tumor load of the pancreatic tumor, and wherein the medicament is to be administered with a chemotherapeutic agent.

8. The use of claim 7, wherein the nonsteroidal selective glucocorticoid receptor modulator is the compound comprising a heteroaryl ketone fused azadecalin having the formula:



9. Use of a nonsteroidal selective glucocorticoid receptor modulator in the manufacture of a medicament for treating a subject hosting a non-ACTH-secreting pancreatic tumor, wherein the nonsteroidal selective glucocorticoid receptor modulator is a compound comprising an octahydro fused azadecalin structure having the formula:



wherein

R^1 is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from R^{1a};

each R^{1a} is independently selected from the group consisting of hydrogen, C_{1-6} alkyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, N-oxide, and C_{3-8} cycloalkyl;

ring J is selected from the group consisting of an aryl ring and a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S;

each R^2 is independently selected from the group consisting of hydrogen, C_{1-6} alkyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} alkyl-C_{1-6}alkoxy, CN, OH, $NR^{2a}R^{2b}$, $C(O)R^{2a}$, $C(O)OR^{2a}$, $C(O)NR^{2a}R^{2b}$, SR^{2a}, $S(O)R^{2a}$, $S(O)_2R^{2a}$, C_{3-8} cycloalkyl, and C_{3-8} heterocycloalkyl having from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S;

alternatively, two R^2 groups on adjacent ring atoms are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 R^{2c} groups;

R^{2a}, R^{2b} and R^{2c} are each independently selected from the group consisting of hydrogen and C_{1-6} alkyl;


each R^{3a} is independently halogen; and

subscript n is an integer from 0 to 3,

or salts and isomers thereof,

wherein the medicament reduces the tumor load of the pancreatic tumor, and wherein the medicament is to be administered with a chemotherapeutic agent.

10. The use of claim 9, wherein the nonsteroidal selective glucocorticoid receptor modulator is the compound comprising an octahydro fused azadecalin having the formula:



11. The use of claim 7, wherein the non-ACTH-secreting pancreatic tumor is an exocrine pancreatic tumor.

12. The use of claim 7, wherein the chemotherapeutic agent is selected from the group consisting of taxanes, alkylating agents, topoisomerase inhibitors, endoplasmic reticulum stress inducing agents, antimetabolites, mitotic inhibitors and combinations thereof.

13. The use of claim 12, wherein the chemotherapeutic agent is a taxane.

14. The use of claim 12, wherein the chemotherapeutic agent is selected from the group consisting of nab-paclitaxel, 5-fluorouracil (5-FU), gemcitabine, cisplatin and capecitabine.

15. The use of claim 9, wherein the non-ACTH-secreting pancreatic tumor is an exocrine pancreatic tumor.

16 The use of claim 9, wherein the chemotherapeutic agent is selected from the group consisting of taxanes, alkylating agents, topoisomerase inhibitors, endoplasmic reticulum stress inducing agents, antimetabolites, mitotic inhibitors and combinations thereof.

17. The use of claim 16, wherein the chemotherapeutic agent is a taxane.

18. The use of claim 16, wherein the chemotherapeutic agent is selected from the group consisting of nab-paclitaxel, 5-fluorouracil (5-FU), gemcitabine, cisplatin and capecitabine.

19. Use of the nonsteroidal selective glucocorticoid receptor modulators of any one of claims 1 and 6-10, in the manufacture of a medicament for treating pancreatic cancer, and wherein the medicament is to be administered with a chemotherapeutic agent.

20. The use of any one of claims 1 to 19, wherein the medicament is to be administered orally, and wherein the medicament is to be administered with a chemotherapeutic agent.

21. The use of any one of claims 1 to 10, wherein the medicament is to be administered intermittently, and wherein the medicament is to be administered with a chemotherapeutic agent.